anti-HLA-A*02/NY-ESO-1 bispecific T-cell engager DS-2243a

A T-cell engaging bispecific antibody directed against the tumor-associated antigen (TAA) NY-ESO-1 complexed with human leukocyte antigen (HLA)-A*02 (HLA-A*02) and an antigen found on T lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, anti-HLA-A*02/NY-ESO-1 bispecific T-cell engager DS-2243a targets and binds to an antigen found on cytotoxic T lymphocytes (CTLs) and NY-ESO-1 presented by HLA-A*02 expressed on tumor cells. This activates and redirects CTLs to NY-ESO-1-expressing tumor cells, which results in the CTL-mediated cell death of NY-ESO-1-expressing tumor cells. NY-ESO-1, a cell surface protein expressed in normal fetal and adult testes, is upregulated in a variety of tumor cell types as a HLA-A*02/NY-ESO-1 complex.